{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:59:58Z","timestamp":1781240398198,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["31902318"],"award-info":[{"award-number":["31902318"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2016YFD0501300"],"award-info":[{"award-number":["2016YFD0501300"]}]},{"name":"the Program for Innovative Research Team in the University of Ministry of Education of China","award":["IRT_17R39"],"award-info":[{"award-number":["IRT_17R39"]}]},{"name":"the Foundation for Innovation and Strengthening School Project of Guangdong, China","award":["2016KCXTD010"],"award-info":[{"award-number":["2016KCXTD010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Gamithromycin is a macrolide approved for the treatment of bovine and swine respiratory diseases. Our study aims to establish the clinical breakpoint and optimum dose regimen for gamithromycin against <jats:italic>Haemophilus parasuis<\/jats:italic> in piglets.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Gamithromycin was well absorbed and fully bioavailable (87.2\u2013101%) after intramuscular and subcutaneous administrations. The MICs of gamithromycin for 192 clinical <jats:italic>H. parasuis<\/jats:italic> isolates ranged from 0.008 to 128\u2009mg\/L and the epidemiological cutoff (ECOFF) was calculated as 1.0\u2009mg\/L. A large potentiation effect of serum on in vitro susceptibility of gamithromycin was observed for <jats:italic>H. parasuis<\/jats:italic>, with broth\/serum ratios of 8.93 for MICs and 4.46 for MBCs, respectively. The postantibiotic effects were 1.5\u2009h (1\u2009\u00d7\u2009MIC) and 2.4\u2009h (4\u2009\u00d7\u2009MIC), and the postantibiotic sub-MIC effects ranged from 2.7 to 4.3\u2009h. Gamithromycin had rapid and concentration-dependent killing against <jats:italic>H. parasuis<\/jats:italic>, and the AUC<jats:sub>24h<\/jats:sub>\/MIC ratio correlated well with ex vivo efficacy (R<jats:sup>2<\/jats:sup>\u2009=\u20090.97). The AUC<jats:sub>24h<\/jats:sub>\/MIC targets in serum associated with bacteriostatic, bactericidal and eradication activities were 15.8, 30.3 and 41.2, respectively. The PK\/PD-based population dose prediction indicated a probability of target attainment (PTA) for the current marketed dose (6\u2009mg\/kg) of 88.9% against <jats:italic>H. parasuis<\/jats:italic>. The calculated gamithromycin dose for a PTA\u2009\u2265\u200990% was 6.55\u2009mg\/kg. Based on Monte Carlo simulations, the PK\/PD cutoff (CO<jats:sub>PD<\/jats:sub>) was determined to be 0.25\u2009mg\/L.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The determined cutoffs and PK\/PD-based dose prediction will be of great importance in gamithromycin resistance surveillance and serve as an important step in the establishment of optimum dose regimen and clinical breakpoints.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12917-020-02300-y","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T16:03:56Z","timestamp":1583424236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Epidemiological and PK\/PD cutoff values determination and PK\/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets"],"prefix":"10.1186","volume":"16","author":[{"given":"Yu-Feng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Xiao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ping","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"2300_CR1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12917-019-1840-x","volume":"15","author":"C Ye","year":"2019","unstructured":"Ye C, Li R, Xu L, Qiu Y, Fu S, Liu Y, Wu Z, Hou Y, Hu CA. Effects of Baicalin on piglet monocytes involving PKC-MAPK signaling pathways induced by Haemophilus parasuis. BMC Vet Res. 2019;15:98.","journal-title":"BMC Vet Res"},{"key":"2300_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12985-017-0890-6","volume":"14","author":"S Liu","year":"2017","unstructured":"Liu S, Li W, Wang Y, Gu C, Liu X, Charreyre C, Fan S, He Q. Coinfection with Haemophilus parasuis serovar 4 increases the virulence of porcine circovirus type 2 in piglets. Virol J. 2017;14:227.","journal-title":"Virol J"},{"key":"2300_CR3","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1128\/JCM.00688-17","volume":"55","author":"A Jia","year":"2017","unstructured":"Jia A, Zhou R, Fan H, Yang K, Zhang J, Xu Y, Wang G, Liao M. Development of serotype-specific PCR assays for typing of Haemophilus parasuis isolates circulating in southern China. J Clin Microbiol. 2017;55:3249\u201357.","journal-title":"J Clin Microbiol"},{"key":"2300_CR4","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1128\/JCM.30.4.862-865.1992","volume":"30","author":"P Kielstein","year":"1992","unstructured":"Kielstein P, Rapp-Gabrielson VJ. Designation of 15 serovars of Haemophilus parasuis on the basis of immunodiffusion using heat-stable antigen extracts. J Clin Microbiol. 1992;30:862\u20135.","journal-title":"J Clin Microbiol"},{"key":"2300_CR5","doi-asserted-by":"publisher","first-page":"e0168903","DOI":"10.1371\/journal.pone.0168903","volume":"11","author":"L Ma","year":"2016","unstructured":"Ma L, Wang L, Chu Y, Li X, Cui Y, Chen S, Zhou J, Li C, Lu Z, Liu J, et al. Characterization of Chinese Haemophilus parasuis isolates by traditional serotyping and molecular serotyping methods. PLoS One. 2016;11:e0168903.","journal-title":"PLoS One"},{"key":"2300_CR6","doi-asserted-by":"publisher","first-page":"e0149132","DOI":"10.1371\/journal.pone.0149132","volume":"11","author":"WD McCaig","year":"2016","unstructured":"McCaig WD, Loving CL, Hughes HR, Brockmeier SL. Characterization and vaccine potential of outer membrane vesicles produced by Haemophilus parasuis. PLoS One. 2016;11:e0149132.","journal-title":"PLoS One"},{"key":"2300_CR7","unstructured":"EMA. CVMP assessment report for ZACTRAN for pigs (EMEA\/V\/C\/000129\/X\/0027). In: The European Agency for the Evaluation of Medicinal Products. European Medicines Agency. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/zactran-v-c-129-x-0027-epar-assessment-report-variation_en.pdf. Accessed 1 Mar 2020."},{"key":"2300_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1365-2885.2009.01125.x","volume":"33","author":"RA Huang","year":"2010","unstructured":"Huang RA, Letendre LT, Banav N, Fischer J, Somerville B. Pharmacokinetics of gamithromycin in cattle with comparison of plasma and lung tissue concentrations and plasma antibacterial activity. J Vet Pharmacol Ther. 2010;33:227\u201337.","journal-title":"J Vet Pharmacol Ther"},{"key":"2300_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/jvp.12267","volume":"39","author":"KD DeDonder","year":"2016","unstructured":"DeDonder KD, Apley MD, Li M, Gehring R, Harhay DM, Lubbers BV, White BJ, Capik SF, KuKanich B, Riviere JE, et al. Pharmacokinetics and pharmacodynamics of gamithromycin in pulmonary epithelial lining fluid in naturally occurring bovine respiratory disease in multisource commingled feedlot cattle. J Vet Pharmacol Ther. 2016;39:157\u201366.","journal-title":"J Vet Pharmacol Ther"},{"key":"2300_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/vr.c6776","volume":"168","author":"D Baggott","year":"2011","unstructured":"Baggott D, Casartelli A, Fraisse F, Manavella C, Marteau R, Rehbein S, Wiedemann M, Yoon S. Demonstration of the metaphylactic use of gamithromycin against bacterial pathogens associated with bovine respiratory disease in a multicentre farm trial. Vet Rec. 2011;168:241.","journal-title":"Vet Rec"},{"key":"2300_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/jvp.12372","volume":"40","author":"P Lees","year":"2017","unstructured":"Lees P, Illambas J, Potter TJ, Pelligand L, Rycroft A, Toutain PL. A large potentiation effect of serum on the in vitro potency of tulathromycin against Mannheimia haemolytica and Pasteurella multocida. J Vet Pharmacol Ther. 2017;40:419\u201328.","journal-title":"J Vet Pharmacol Ther"},{"key":"2300_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.36.1.10","volume":"36","author":"H Pruul","year":"1992","unstructured":"Pruul H, McDonald PJ. Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum. Antimicrob Agents Chemother. 1992;36:10\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"2300_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3389\/fphar.2017.00684","volume":"8","author":"YF Zhou","year":"2017","unstructured":"Zhou YF, Peng HM, Bu MX, Liu YH, Sun J, Liao XP. Pharmacodynamic evaluation and PK\/PD-based dose prediction of Tulathromycin: a potential new indication for Streptococcus suis infection. Front Pharmacol. 2017;8:684.","journal-title":"Front Pharmacol"},{"key":"2300_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1365-2885.2012.01397.x","volume":"36","author":"M Rose","year":"2013","unstructured":"Rose M, Menge M, Bohland C, Zschiesche E, Wilhelm C, Kilp S, Metz W, Allan M, Ropke R, Nurnberger M. Pharmacokinetics of tildipirosin in porcine plasma, lung tissue, and bronchial fluid and effects of test conditions on in vitro activity against reference strains and field isolates of Actinobacillus pleuropneumoniae. J Vet Pharmacol Ther. 2013;36:140\u201353.","journal-title":"J Vet Pharmacol Ther"},{"key":"2300_CR15","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/cid\/cis473","volume":"55","author":"JM Buyck","year":"2012","unstructured":"Buyck JM, Plesiat P, Traore H, Vanderbist F, Tulkens PM, Van Bambeke F. Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability. Clin Infect Dis. 2012;55:534\u201342.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2300_CR16","doi-asserted-by":"publisher","first-page":"1601847","DOI":"10.1183\/13993003.01847-2016","volume":"49","author":"Muhammad-Hariri Mustafa","year":"2017","unstructured":"Mustafa MH, Khandekar S, Tunney MM, Elborn JS, Kahl BC, Denis O, Plesiat P, Traore H, Tulkens PM, Vanderbist F, et al. Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients. Eur Respir J. 2017;49:1601847.","journal-title":"European Respiratory Journal"},{"key":"2300_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.tvjl.2013.05.025","volume":"197","author":"JD Mitchell","year":"2013","unstructured":"Mitchell JD, Goh S, McKellar QA, McKeever DJ. In vitro pharmacodynamics of gamithromycin against Mycoplasma mycoides subspecies mycoides small Colony. Vet J. 2013;197:806\u201311.","journal-title":"Vet J"},{"key":"2300_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vetmic.2013.07.027","volume":"168","author":"B Zhang","year":"2014","unstructured":"Zhang B, Tang C, Liao M, Yue H. Update on the pathogenesis of Haemophilus parasuis infection and virulence factors. Vet Microbiol. 2014;168:1\u20137.","journal-title":"Vet Microbiol"},{"key":"2300_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.vetmic.2013.12.021","volume":"171","author":"MG Papich","year":"2014","unstructured":"Papich MG. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs. Vet Microbiol. 2014;171:480\u20136.","journal-title":"Vet Microbiol"},{"key":"2300_CR20","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.3382\/ps\/pev217","volume":"94","author":"A Watteyn","year":"2015","unstructured":"Watteyn A, Devreese M, De Baere S, Wyns H, Plessers E, Boyen F, Haesebrouck F, De Backer P, Croubels S. Pharmacokinetic and pharmacodynamic properties of gamithromycin in Turkey poults with respect to Ornithobacterium rhinotracheale. Poult Sci. 2015;94:2066\u201374.","journal-title":"Poult Sci"},{"key":"2300_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.rvsc.2013.11.012","volume":"96","author":"H Wyns","year":"2014","unstructured":"Wyns H, Meyer E, Plessers E, Watteyn A, De Baere S, De Backer P, Croubels S. Pharmacokinetics of gamithromycin after intravenous and subcutaneous administration in pigs. Res Vet Sci. 2014;96:160\u20133.","journal-title":"Res Vet Sci"},{"key":"2300_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/jvp.12333","volume":"40","author":"PL Toutain","year":"2017","unstructured":"Toutain PL, Potter T, Pelligand L, Lacroix M, Illambas J, Lees P. Standard PK\/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf. J Vet Pharmacol Ther. 2017;40:16\u201327.","journal-title":"J Vet Pharmacol Ther"},{"key":"2300_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3389\/fphar.2018.00765","volume":"9","author":"Z Lei","year":"2018","unstructured":"Lei Z, Liu Q, Qi Y, Yang B, Khaliq H, Xiong J, Moku GK, Ahmed S, Li K, Zhang H, et al. Optimal regimens and cutoff evaluation of Tildipirosin against Pasteurella multocida. Front Pharmacol. 2018;9:765.","journal-title":"Front Pharmacol"},{"key":"2300_CR24","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.3389\/fmicb.2017.02344","volume":"8","author":"PL Toutain","year":"2017","unstructured":"Toutain PL, Bousquet-Melou A, Damborg P, Ferran AA, Mevius D, Pelligand L, Veldman KT, Lees P. En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach. Front Microbiol. 2017;8:2344.","journal-title":"Front Microbiol"},{"key":"2300_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tvjl.2017.10.004","volume":"228","author":"JD Turnidge","year":"2017","unstructured":"Turnidge JD, Martinez MN. Proposed method for estimating clinical cut-off (COCL) values: an attempt to address challenges encountered when setting clinical breakpoints for veterinary antimicrobial agents. Vet J. 2017;228:33\u20137.","journal-title":"Vet J"},{"key":"2300_CR26","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","volume":"18","author":"JW Mouton","year":"2012","unstructured":"Mouton JW, Brown DF, Apfalter P, Canton R, Giske CG, Ivanova M, MacGowan AP, Rodloff A, Soussy CJ, Steinbakk M, et al. The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect. 2012;18:E37\u201345.","journal-title":"Clin Microbiol Infect"},{"key":"2300_CR27","unstructured":"CLSI. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals: approved standard, 5th ed. CLSI document VET01. Wayne:\u00a0Clinical and Laboratory Standards Institute;\u00a02018."},{"key":"2300_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12917-015-0604-5","volume":"11","author":"J Sun","year":"2015","unstructured":"Sun J, Xiao X, Huang RJ, Yang T, Chen Y, Fang X, Huang T, Zhou YF, Liu YH. In vitro dynamic pharmacokinetic\/Pharmacodynamic (PK\/PD) study and COPD of Marbofloxacin against Haemophilus parasuis. BMC Vet Res. 2015;11:293.","journal-title":"BMC Vet Res"},{"key":"2300_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12917-015-0343-7","volume":"11","author":"X Xiao","year":"2015","unstructured":"Xiao X, Sun J, Chen Y, Huang RJ, Huang T, Qiao GG, Zhou YF, Liu YH. In vitro dynamic pharmacokinetic\/pharmacodynamic (PK\/PD) modeling and PK\/PD cutoff of cefquinome against Haemophilus parasuis. BMC Vet Res. 2015;11:33.","journal-title":"BMC Vet Res"},{"key":"2300_CR30","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3855\/jidc.7787","volume":"10","author":"LZ Moreno","year":"2016","unstructured":"Moreno LZ, Silva GF, Gomes VT, Matajira CE, Silva AP, Mesquita RE, Lotto NP, Ferreira TS, Christ AP, Sato MI, et al. Application of protein profiling of virulent Haemophilus parasuis by MALDI-TOF mass spectrometry. J Infect Dev Ctries. 2016;10:678\u201381.","journal-title":"J Infect Dev Ctries"},{"key":"2300_CR31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/jvp.12402","volume":"40","author":"S Berlin","year":"2017","unstructured":"Berlin S, Randow T, Scheuch E, Grube M, Venner M, Siegmund W. Pharmacokinetics and pulmonary distribution of gamithromycin after intravenous administration in foals. J Vet Pharmacol Ther. 2017;40:406\u201310.","journal-title":"J Vet Pharmacol Ther"},{"key":"2300_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1365-2885.2004.00604.x","volume":"27","author":"PL Toutain","year":"2004","unstructured":"Toutain PL, Bousquet-Melou A. Bioavailability and its assessment. J Vet Pharmacol Ther. 2004;27:455\u201366.","journal-title":"J Vet Pharmacol Ther"},{"key":"2300_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1469-0691.2006.01377.x","volume":"12","author":"J Turnidge","year":"2006","unstructured":"Turnidge J, Kahlmeter G, Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect. 2006;12:418\u201325.","journal-title":"Clin Microbiol Infect"},{"key":"2300_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.anaerobe.2017.08.006","volume":"48","author":"MT Tao","year":"2017","unstructured":"Tao MT, Zhou YF, Sun J, Liu YH, Liao XP. Establishment of valnemulin susceptibility breakpoint against Clostridium perfringens in rabbits. Anaerobe. 2017;48:118\u201320.","journal-title":"Anaerobe"},{"key":"2300_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.anaerobe.2016.04.005","volume":"39","author":"YF Zhou","year":"2016","unstructured":"Zhou YF, Yu Y, Sun J, Tao MT, Zhou WJ, Li X, Liao XP, Liu YH. Ex vivo pharmacokinetic\/pharmacodynamic relationship of valnemulin against Clostridium perfringens in plasma, the small intestinal and caecal contents of rabbits. Anaerobe. 2016;39:150\u20137.","journal-title":"Anaerobe"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-020-02300-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12917-020-02300-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-020-02300-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:12:39Z","timestamp":1614903159000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-020-02300-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2300"],"URL":"https:\/\/doi.org\/10.1186\/s12917-020-02300-y","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]},"assertion":[{"value":"18 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies were carried out in accordance with the recommendations of ethical guidelines of South China Agricultural University (SCAU). The protocol of in vivo experiment and strain isolation procedures from animals were approved by the SCAU Institutional Animal Ethics Committee (SCAU 2018A014). Individual written informed consent for the use of samples was obtained from all animal owners.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}